Company: XAIR
Filing Date: 2025-02-10
Form Type: 10-Q
Source: 0001493152-25-005678
Chunk: 110

Company: Beyond Air, Inc.
Filing Date: 2025-02-10
Form: 10-Q
Item: Part II, Item 8
Chunk 110
---
 9) 
     -  
     400 
  
    Circassia settlement – current portion (Note 8) 
     -  
     4,500 
  
    Deferred revenue 
     -  
     138 
  
    Accrued interest 
     98  
     23 
  
    Goods received not invoiced 
     298  
     356 
  
    Other 
     311  
     252 

    Total short-term accrued expenses 
    $2,631  
    $8,402 

     21 

BEYOND
AIR, INC. AND SUBSIDIARIES

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE
7 BASIC AND DILUTED NET INCOME (LOSS) PER SHARE OF COMMON STOCK

The
following potentially dilutive securities were not included in the calculation of diluted net income (loss) per share attributable to
common stockholders of Beyond Air because their effect would have been anti-dilutive for the periods presented:

 SCHEDULE
OF POTENTIAL ANTI-DILUTIVE SECURITIES

    December 31, 2024  
    December 31, 2023 

    Common stock warrants 
     80,182,796  
     694,363 
  
    Common stock options 
     10,594,598  
     7,978,094 
  
    Restricted shares 
     367,800  
     748,400 
  
    Loan and Security – conversion feature 
     -  
     392,465 
  
    Total 
     91,145,194  
     9,813,322 
  
    Anti-dilutive
    securities 
     91,145,194  
     9,813,322 

NOTE
8 CIRCASSIA AGREEMENT

On
January 23, 2019, the Company entered into an agreement for commercial rights (the “Circassia Agreement”) with Circassia
Limited and its affiliates (collectively, “Circassia”) for PPHN and future related indications at concentrations of <
80 ppm in the hospital setting in the United States and China. On December 18, 2019, the Company terminated the Circassia Agreement.

On
May 25, 2021, the Company and Circassia